A Meta-analysis Exploring the Efficacy of Neuropathic Pain Medication for Low Back Pain or Spine-Related Leg Pain: Is Efficacy Dependent on the Presence of Neuropathic Pain?
Drugs · 2024-12 · 84 (12) · 1603-1636
DOI: 10.1007/s40265-024-02085-6 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Drugs, online erschienen am 26.10.2024. Verfasst von Jennifer Ward und 5 weiteren Autor:innen. Beteiligte Einrichtung: Kent Community Hospitals NHS Foundation Trust, Sevenoaks Hospital, Hospital Road, Sevenoaks, Kent, TN11 3PG, UK. Hauptthemen laut MEDLINE: Low Back Pain, Neuralgia. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Wellcome Trust.
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVE: Highly variable pain mechanisms in people with low back pain or spine-related leg pain might contribute to inefficacy of neuropathic pain medication. This meta-analysis aimed to determine how neuropathic pain is identified in clinical trials for people taking neuropathic pain medication for low back pain or spine-related leg pain and whether subgrouping based on the presence of neuropathic pain influences efficacy. METHODS: EMBASE, MEDLINE, Cochrane Central, CINAHL [EBSCO], APA PsycINFO, ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry were searched from inception to 14 May, 2024. Randomized and crossover trials comparing first-line neuropathic pain medication for people with low back pain or spine-related leg pain to placebo or usual care were included. Two independent authors extracted data. Random-effects meta-analyses of all studies combined, and pre-planned subgroup meta-analyses based on the certainty of neuropathic pain (according to the neuropathic pain Special Interest Group [NeuPSIG] neuropathic pain grading criteria) were completed. Certainty of evidence was judged using the grading of recommendations assessment development and evaluation [GRADE] framework. RESULTS: Twenty-seven included studies reported on 3619 participants. Overall, 33% of studies were judged unlikely to include people with neuropathic pain, 26% remained unclear. Only 41% identified people with possible, probable, or definite neuropathic pain. For pain, general analyses revealed only small effects at short term (mean difference [MD] - 9.30 [95% confidence interval [CI] - 13.71, - 4.88], I2 = 87%) and medium term (MD - 5.49 [95% CI - 7.24, - 3.74], I2 = 0%). Subgrouping at short term revealed studies including people with definite or probable neuropathic pain showed larger effects on pain (definite; MD - 16.65 [95% CI - 35.95, 2.65], I2 = 84%; probable; MD - 10.45 [95% CI - 14.79, - 6.12], I2 = 20%) than studies including people with possible (MD - 5.50 [95% CI - 20.52, 9.52], I2 = 78%), unlikely (MD - 6.67 [95% CI - 10.58, 2.76], I2 = 0%), or unclear neuropathic pain (MD - 8.93 [95% CI - 20.57, 2.71], I2 = 96%). Similarly, general analyses revealed negligible effects on disability at short term (MD - 3.35 [95% CI - 9.00, 2.29], I2 = 93%) and medium term (MD - 4.06 [95% CI - 5.63, - 2.48], I2 = 0%). Sub-grouping at short term revealed larger effects in studies including people with definite/probable neuropathic pain (MD - 9.25 [95% CI - 12.59, - 5.90], I2 = 2%) compared with those with possible/unclear/unlikely neuropathic pain (MD -1.57 [95% CI - 8.96, 5.82] I2 = 95%). Medium-term outcomes showed a similar trend, but were limited by low numbers of studies. Certainty of evidence was low to very low for all outcomes. CONCLUSIONS: Most studies using neuropathic pain medication for low back pain or spine-related leg pain fail to adequately consider the presence of neuropathic pain. Meta-analyses suggest neuropathic pain medication may be most effective in people with low back pain or spine-related leg pain with a definite/probable neuropathic pain component. However, the low to very low certainty of evidence and poor identification of neuropathic pain in most studies prevent firm recommendations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Kent Community Hospitals NHS Foundation Trust, Sevenoaks Hospital, Hospital Road, Sevenoaks, Kent, TN11 3PG, UK.
- Sussex Community NHS Foundation Trust, Trust HQ Brighton General Hospital, Brighton, BN2 3EW, UK.
- University Hospital Sussex, Worthing Hospital, Lyndhurst road,, Worthing, BN11 2DH, UK.
- University of Suffolk, 19 Neptune Quay, Ipswich, IP4 1QJ, UK.
- Nuffield Department of Clinical Neurosciences, Oxford University, John Radcliffe Hospital, Oxford, OX3 9DU, UK. annina.schmid@neuro-research.ch.
- School of Sport and Health Science, University of Brighton, Robert Dodd Building, 49 Darley road, Eastbourne, BN20 7UR , UK.
Förderung
- Wellcome Trust
Zitieren
APA
Ward, J., Grinstead, A., Kemp, A., Kersten, P., Schmid, A. B., & Ridehalgh, C. (2024). A Meta-analysis Exploring the Efficacy of Neuropathic Pain Medication for Low Back Pain or Spine-Related Leg Pain: Is Efficacy Dependent on the Presence of Neuropathic Pain?. Drugs, 84(12), 1603-1636. https://doi.org/10.1007/s40265-024-02085-6
Vancouver
Ward J, Grinstead A, Kemp A, Kersten P, Schmid AB, Ridehalgh C. A Meta-analysis Exploring the Efficacy of Neuropathic Pain Medication for Low Back Pain or Spine-Related Leg Pain: Is Efficacy Dependent on the Presence of Neuropathic Pain?. Drugs. 2024;84(12):1603-1636. doi:10.1007/s40265-024-02085-6
BibTeX
@article{Ward2024,
author = {Ward, Jennifer and Grinstead, Anthony and Kemp, Amy and Kersten, Paula and Schmid, Annina B and Ridehalgh, Colette},
title = {A Meta-analysis Exploring the Efficacy of Neuropathic Pain Medication for Low Back Pain or Spine-Related Leg Pain: Is Efficacy Dependent on the Presence of Neuropathic Pain?},
journal = {Drugs},
year = {2024},
volume = {84},
number = {12},
pages = {1603--1636},
doi = {10.1007/s40265-024-02085-6}
}
EUVIMED